PHK
TBPH icon

Point72 Hong Kong’s Theravance Biopharma TBPH Stock Holding History

Point72 Hong Kong’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-400
Closed -$3.57K – 687
2025
Q1 		$3.57K Buy
+400
New +$3.72K ﹤0.01% 449
2021
Q4 		– Sell
-775
Closed -$6K – 2378
2021
Q3 		$6K Buy
+775
New +$8.67K ﹤0.01% 1831

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ICM
Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Point72 Hong Kong's TBPH Position: Q2 2025 in Review

Point72 Hong Kong sold out of Theravance Biopharma (TBPH) in Q2 2025, closing a stake of 400 shares — an estimated $3.57K sold.

Point72 Hong Kong first reported a position in TBPH in Q3 2021 and held it in 2 quarters. The position peaked at $6K in Q3 2021. 135 funds tracked by Wall St. Rank hold TBPH as of Q2 2025.

  • Point72 Hong Kong reported no remaining Theravance Biopharma position as of Q2 2025 after selling out during the quarter.
  • Point72 Hong Kong sold 400 Theravance Biopharma shares in Q2 2025, an estimated $3.57K.
  • Point72 Hong Kong first reported a position in Theravance Biopharma in Q3 2021 and held it in 2 quarters.
  • Point72 Hong Kong's Theravance Biopharma position peaked at $6K in Q3 2021.
  • 135 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2025.

Based on Point72 Hong Kong's 13F filing for Q2 2025, filed 14 Aug 2025.